Business
Cosmos Health Holds EU Distribution Rights for Virax Biolabs’ Mpox (formerly Monkeypox) Virus Real-Time PCR Detection Kits
CHICAGO, IL / ACCESSWIRE / August 21, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global
About this update from Cosmos Health Inc.
[{"type":"text","content":"CHICAGO, IL / ACCESSWIRE / August 21, 2024 / Cosmos Health Inc. (\"Cosmos Health\" or the \"Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today, pursuant to its agreement with Virax Biolabs (NASDAQ: VRAX), that it continues to hold the rights to distribute mpox virus real-time PCR detection kits, with exclusive distribution rights in Greece and Cyprus, and non-exclusive distribution rights across Europe.On August 14, 2024, World Health Organization (WHO) Director-General Dr. Tedros Adhanom Ghebreyesus determined that the upsurge of mpox in the Democratic Republic of the Congo and a growing number of countries in Africa constitutes a public health emergency of international concern under the International Health Regulations. On August 15, 2024, the WHO confirmed that Sweden became the first country outside the African continent to confirm the new mpox strain.Greg Siokas, CEO of Cosmos Health, stated: \"In these challenging times, as mpox emerges in Europe, Cosmos is well-positioned to support governments and public health authorities in the EU/EEA by enhancing preparedness, planning, and awareness efforts to ensure rapid detection and effective response.\"About Virax BiolabsVirax Biolabs, founded in 2013, is a UK based diagnostics company focused on the prevention, detection and diagnosis of viral diseases, with a particular interest in the field of immunology. The test is intended to aid in the rapid diagnosis of mpox virus in human serum and lesion exudate specimens, providing a preliminary test result. Clinical correlation with patient history and other diagnostic information is necessary to determine patient infection status.About Cosmos Health Inc.Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe® and C-Sept®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactu...